Test Code Billings Clinic: 4578 Mayo: A2PI Alpha-2 Plasmin Inhibitor, Plasma
Reporting Name
Alpha-2 Plasmin Inhibitor, PPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Diagnosing congenital alpha-2 plasmin inhibitor deficiencies (rare)
Providing a complete assessment of disseminated intravascular coagulation, intravascular coagulation and fibrinolysis, or hyperfibrinolysis (primary fibrinolysis), when measured in conjunction with fibrinogen, fibrin D-dimer, fibrin degradation products, soluble fibrin monomer complex, and plasminogen
Evaluating liver disease
Evaluating the effects of fibrinolytic or antifibrinolytic therapy
Method Name
Chromogenic
Specimen Required
Specimen Type: Platelet-poor plasma
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
2. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
3. Aliquot plasma into a plastic vial leaving 0.25 mL in the bottom of centrifuged vial.
4. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Specimen Type
Plasma Na CitSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Reference Values
Adults: 80-140%
Normal, full-term, and premature infants may have mildly decreased levels (≥50%) that reach adult levels within 90 days postnatal.*
*See Pediatric Hemostasis References section in Coagulation Guidelines for Specimen Handling and Processing.
Interpretation
Patients with congenital homozygous deficiency (with levels of <10%) are clinically affected (bleeding). Heterozygous individuals having levels of 30% to 60% of mean normal activity are usually asymptomatic.
Lower than normal levels may be suggestive of consumption due to activation of plasminogen and its inhibition by alpha-2 plasmin inhibitor.
The clinical significance of high levels of alpha-2 plasmin inhibitor is unknown.
Day(s) Performed
Monday through Friday
Report Available
3 to 7 daysTest Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
85410
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
A2PI | Alpha-2 Plasmin Inhibitor, P | 27810-1 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
A2PI | Alpha-2 Plasmin Inhibitor, P | 27810-1 |
Forms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.